Up­dat­ed: Roivant’s FcRn an­ti­body for au­toim­mune dis­ease shows ear­ly po­ten­tial in study with healthy sub­jects

Roivant Sci­ences’ Im­muno­vant has un­veiled bio­mark­er re­sults for its au­toim­mune dis­ease an­ti­body drug from a Phase I healthy sub­ject tri­al.

The sub­cu­ta­neous drug, dubbed IMVT-1402, tar­gets the neona­tal frag­ment crys­tal­liz­able re­cep­tor (FcRn) for im­munoglob­u­lin G (IgG)-me­di­at­ed au­toim­mune dis­eases.

Im­muno­vant’s stock price $IMVT soared by 87% to about $38.00 on Tues­day in re­sponse to the da­ta, while Roivant $ROIV — which owns a con­trol­ling share of Im­muno­vant — went up by 23% to $12.60.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER